Company: KVACU
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0001213900-25-021314
Chunk: 568

Company: Keen Vision Acquisition Corp.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 5
Chunk 568
---
 Name
     
    Age
     
    Position
  
    WONG, Kenneth Ka Chun
     
    51
     
    Chairman and Chief Executive Officer
  
    DAVIDKHANIAN, Alex
     
    50
     
    Chief Financial Officer, Director
  
    DING, Yibing Peter
     
    57
     
    Independent Director
  
    CHU, William
     
    52
     
    Independent Director
  
    YU, Albert Cheung-Hoi
     
    69
     
    Independent Director

Below is a summary of the
business experience of each our executive officers and directors:

Mr. WONG, Kenneth Ka
Chun

Mr.
Kenneth Wong, our CEO and Chairman since September 2021, has over 25 years of experience in finance and operations, with a track record
of executing notable M&A deals. Since their inceptions in September 2011 and December 2008 respectively, Mr. Kenneth Wong has been
the founder, Chairman and CEO of both Keen Vision Capital (BVI) Limited, a single-family office specializing in PE investments with minority
stakes, which has a track record of successful exits in the high technology, agriculture, and consumer goods industries, and Keen Vision
International Limited, a PE investment firm targeting controlling or majority stakes. During Mr. Kenneth Wong’s time in both companies,
he has been managing fundraising process and operations, providing restructuring, strategic and listing advice for investee companies,
and all investments were executed with a view to exit via listing on an international stock exchange or trade sale.

Prior
to this, from October 2002 to February 2004, Mr. Kenneth Wong was first the CFO of the Shanghai A-share listed pharmaceutical research &
development and manufacturing subsidiary Topsun Science and Technology Company Limited (SH600771), before becoming the Senior Vice President
of the Topsun Pharmaceutical Group from February 2004 to August 2008. During his time at Topsun, Mr. Kenneth Wong oversaw acquisitions
of two leading Chinese national pharmaceuticals, Yunnan Baiyao and Shanxi Guangyuyuan, as well as the sale of Qidong Gaitianli Pharmaceutical
Co., Ltd. to Germany’s Bayer Group, in what was then the first major cross-border M&A deal in the Chinese pharmaceutical industry,
and also the first cross-border acquisition of a Chinese pharmaceutical company by a Fortune 50 company. From September 2001 to